Sorrento Reports Results of COVISTIX COVID-19 Test to Detects Omicron Variant
Shots:
- The company reported the initial lab results of its COVISTIX COVID-19 virus rapid antigen detection test which showed its ability to detect Omicron variant along with the original SARS-CoV-2 virus and other VOCs
- In a laboratory setting, COVISTIX can detect the Omicron N protein at a lower level over other COVID-19 rapid antigen tests that were EUA approved and commercially available. Additionally, COVISTIX demonstrated ~20% higher sensitivity in a real-world clinical study including asymptomatic patients
- COVISTIX is currently approved in Mexico, Brazil and is CE marked in the EU. The company is currently building up its manufacturing capacity in the US
Ref: Globe Newswire | Image: Sorrento
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com